Real-time Stock quotes, portfolio, LIVE TV and more.
Aug 18, 2012, 05.02 PM IST
Pharma major Cipla today said it is hopeful of achieving 12-15% revenue growth in the current financial year.
He said Cipla's turnover crossed Rs 7,000 crore mark with a profit of Rs 1,100 crore in FY12 and "we hope to cross the magical figure of Rs 10,000 crore within a few years".
The drugmaker is setting up API facilities at Patalganga (near Mumbai), Bengaluru and Kurkumbh (near Pune) which are expected to be completed in the current year. It is also upgrading its R&D center at Vikhroli in Mumbai and has set up a new R&D establishment at Patalganga.
Cipla's Indore formulation unit is now contributing Rs 700 crore to export revenue and it is yet to reach optimum capacity. The firm has made significant investment in making of biosimilar drugs, both in India and China. This activity will have immense potential in the coming years, he said.
The company has ventured into research in stem cells with a major investment in Stempeutics Research Pvt Ltd at Bengaluru. "We are hopeful of products based on stem cells reaching the market in 3-5 years," Hamied said.
Commenting on future plans, Hamied said the company has over 100 granted patents on APIs (active pharmaceutical ingredients), formulations and medical devices.
In the US, Cipla has over 130 Drug Master Files (DMFs) for active ingredients, 105 registered generic approvals and is awaiting 26 approvals, including 18 new drug applications. In other regulated markets, including the European Union, the company has over 100 approved API and DMFs.
May 21 2013, 13:56
- in Results Boardroom
May 21 2013, 11:05
- in MARKET OUTLOOK